Forecast
The analysts' average price target is €291.63 (+0.25%). The median is €291.63 (+0.25%).
| Buy |
Â
9 |
| Hold |
Â
13 |
| Sell |
Â
0 |
Discussions in the community
Translated from German
What are your current top stock picks?As the title suggests, I'm curious which stocks you currently find interesting. The goal is to discover a few interesting titles that I might have overlooked. Let me start with stocks I'm currently…
u user_acfe44 IV in Schnack
2 8
News Go to news feed
Penumbra: stroke system Thunderbolt reaches targets in THUNDER study
Penumbra reports that the vacuum thrombectomy system Thunderbolt met the predefined performance goal in the single-arm, multicenter THUNDER study: 87.5% successful reperfusion (mTICI 2b-3). First-pass reperfusion was achieved in 64.8%, mTICI 2c-3 in 70.4%, median time to revascularization was 20 minutes, and complete clot removal was achieved in 83% of cases. Device- or procedure-related serious adverse events occurred in 2.8%, symptomatic intracranial hemorrhage in 0.9%, and 90-day mortality was 11.7%. Thunderbolt recently received FDA approval and the CE mark. » More on de.investing.com
Penumbra reaches 52-week high at $328.69
Penumbra shares closed at a new 52-week high of $328.69. The medical device company has a market capitalization of $12.93 billion, a P/E ratio of 75.62 and revenue growth of 17.27% over the past 12 months. For Q4 2025 Penumbra reported revenue of $385.4 million and adjusted EBITDA of $79.1 million, both above analyst expectations, and shareholders approved a merger with Boston Scientific. Analysts differ on the stock’s valuation: InvestingPro rates it as overvalued, UBS remains at “neutral” with a $374 price target, and Evercore ISI raised its target to $360. » More on de.investing.com
Penumbra shareholders approve merger with Boston Scientific
Penumbra shareholders voted at a special general meeting to approve the merger agreement with Boston Scientific (28,564,786 yes votes, 85,334 no votes). The deal would make Penumbra a wholly owned subsidiary of Boston Scientific; completion remains subject to regulatory approvals (including Hart‑Scott‑Rodino, antitrust and foreign investment reviews). Penumbra reported Q4 2025 revenue of $385.4 million and adjusted EBITDA of $79.1 million, beating expectations; UBS maintained a "Neutral" rating, and Evercore ISI raised its price target. Additionally, the STORM‑PE study showed improved functional outcomes for vacuum thrombectomy versus pulmonary embolism. » More on de.investing.com
Penumbra reaches new all-time high at $352.30 and reports takeover offer from Boston Scientific
Penumbra shares rose to an all-time high of $352.30 after a strong price rally over the past year and a six-month gain of more than 52%. InvestingPro considers the stock overvalued versus fair value, the RSI signals overbought conditions, while the financial position is rated "OUTSTANDING." Penumbra released preliminary Q4 2025 revenue (USD 383.0–384.8 million) and full-year 2025 revenue guidance (approx. USD 1,401–1,403 million). Boston Scientific announced a takeover offer for Penumbra at USD 374 per share, prompting several research houses to cut their ratings to hold/neutral but set price targets at USD 374. » More on de.investing.com
Penumbra reports preliminary Q4 revenue growth of over 21%
Medical device maker Penumbra expects preliminary Q4 2025 revenues of $383.0 million to $384.8 million, an increase of about 21.4% to 22.0% year-over-year. Excluding China, growth in the quarter was about 23.2% to 23.8%. For full-year 2025 the company forecasts revenues of $1,401.3 million to $1,403.1 million (growth ~17.3%–17.5%). Preliminary gross margin for Q4 is estimated at 67.9%–68.1%; preliminary operating income for Q4 is $56.9 million–$60.4 million (operating margin 14.8%–15.7%). All figures are preliminary and unaudited; no date was given for the full filings. » More on de.investing.com
Financials
In the last quarter, Penumbra Inc had revenue of €362.1m and net profit of €37.33m
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 362.1m | 19.81% |
| Gross profit | 247.47m | 20.79% |
| Net profit | 37.33m | 4.47% |
| EBITDA | 54.81m | 16.63% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €11.46bn |
Number of shares | 39.41m |
52-week high/low | €330.28 - €259.69 |
| Dividends | No |
Beta | 0.69 |
P/E ratio | 79.98 |
PEG ratio | -13.56 |
P/B ratio | 7.94 |
P/S ratio | 8.06 |
Company profile
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
| Name | Penumbra Inc |
| CEO | Adam Elsesser |
| Headquarters | Alameda,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 18/09/2015 |
| Employees | 4,700 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | PEN |
Frankfurt | 0P8.F |
DĂĽsseldorf | 0P8.DU |
SIX | 0P8.SW |
MĂĽnchen | 0P8.MU |